-
公开(公告)号:US20130274227A1
公开(公告)日:2013-10-17
申请号:US13830712
申请日:2013-03-14
IPC分类号: C07D231/38 , A61K31/4439 , C07D401/12 , C07D405/12 , A61K31/4155 , C07D417/12 , A61K31/427 , C07D403/12 , A61K45/06 , A61K31/506 , C07D409/14 , A61K31/4184 , A61K31/4178 , A61K31/496 , A61K31/5377 , A61K31/454 , C07D409/12 , C07F5/02 , A61K31/69 , A61K31/415
CPC分类号: C07D413/12 , A61K31/415 , A61K31/4155 , A61K31/416 , A61K31/4178 , A61K31/4184 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/69 , A61K45/06 , C07D231/38 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07F5/025
摘要: Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.
-
2.
公开(公告)号:US20110218207A1
公开(公告)日:2011-09-08
申请号:US13038251
申请日:2011-03-01
申请人: Tai Wei Ly , Garrett Thomas Potter
发明人: Tai Wei Ly , Garrett Thomas Potter
IPC分类号: A61K31/495 , C07D295/26 , C07C311/18 , A61P29/00 , A61P11/06 , A61P1/00 , A61P17/10 , A61P1/04 , A61P35/02 , A61P11/00 , A61P17/06 , A61P19/02 , A61P9/00
CPC分类号: C07D295/26 , C07B59/002
摘要: Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
摘要翻译: 本文提供了可用于调节CCR3活性的同位素富集的芳基磺酰胺,例如式I,以及其药物组合物。 本文还提供其用于治疗,预防或改善CCR3介导的病症,疾病或病症的一种或多种症状的方法。
-
公开(公告)号:US20100273785A1
公开(公告)日:2010-10-28
申请号:US12764249
申请日:2010-04-21
申请人: Tai Wei Ly , Garrett Thomas Potter
发明人: Tai Wei Ly , Garrett Thomas Potter
IPC分类号: A61K31/54 , A61K31/5375 , A61K31/495 , A61K31/4453 , C07D295/26 , C07D241/18 , C07D211/96 , A61P11/06 , A61P29/00 , A61P37/02 , A61P31/18 , A61P25/28 , A61P11/00 , A61P37/08
CPC分类号: C07D295/26 , A61K31/445 , A61K31/4453 , A61K31/495 , A61K31/5375 , A61K31/54 , A61K45/06 , C07D211/96 , C07D241/04 , C07D241/08 , C07D265/30
摘要: Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists of Formula I or II, and pharmaceutical compositions thereof: wherein X, Y, Z, and R1-R5 are as defined herein. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
摘要翻译: 本文提供式I或II的2,5-二取代芳基磺酰胺CCR3拮抗剂及其药物组合物:其中X,Y,Z和R 1 -R 5如本文所定义。 本文还提供其用于治疗,预防或改善CCR3介导的病症,疾病或病症的一种或多种症状的方法。
-
公开(公告)号:US08999995B2
公开(公告)日:2015-04-07
申请号:US13038251
申请日:2011-03-01
申请人: Tai Wei Ly , Garrett Thomas Potter
发明人: Tai Wei Ly , Garrett Thomas Potter
IPC分类号: A61K31/495 , C07D295/26 , C07B59/00
CPC分类号: C07D295/26 , C07B59/002
摘要: Provided herein are isotopically enriched arylsulfonamides, for example, of Formula I, that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
摘要翻译: 本文提供了可用于调节CCR3活性的同位素富集的芳基磺酰胺,例如式I,以及其药物组合物。 本文还提供其用于治疗,预防或改善CCR3介导的病症,疾病或病症的一种或多种症状的方法。
-
公开(公告)号:US08314116B2
公开(公告)日:2012-11-20
申请号:US12679893
申请日:2008-09-24
IPC分类号: C07D239/47 , A61K31/505
CPC分类号: C07D239/47
摘要: Provided herein are 2-S-benzyl pyrimidine compounds having CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity, useful for the prophylaxis and treatment of diseases associated with CRTH2 activity, including the treatment of allergic diseases, eosinophil-related diseases and basophil-related diseases.
摘要翻译: 本文提供了具有CRTH2(G蛋白偶联化学引诱物受体,Th2细胞表达)拮抗活性的2-S-苄基嘧啶化合物,可用于预防和治疗与CRTH2活性相关的疾病,包括治疗过敏性疾病,嗜酸性粒细胞 相关疾病和嗜碱性粒细胞相关疾病。
-
公开(公告)号:US08741894B2
公开(公告)日:2014-06-03
申请号:US13050831
申请日:2011-03-17
IPC分类号: A61K31/5377 , A61K31/4468 , A61K31/454 , A61K31/4545 , A61K31/496 , C07D211/96 , C07D401/12 , C07D401/04 , C07D413/12
CPC分类号: C07D211/96 , A61K31/4468 , A61K31/4525 , C07D401/04 , C07D405/12 , C07D413/12 , C07D417/12
摘要: Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
-
公开(公告)号:US08318747B2
公开(公告)日:2012-11-27
申请号:US12764249
申请日:2010-04-21
申请人: Tai Wei Ly , Garrett Thomas Potter
发明人: Tai Wei Ly , Garrett Thomas Potter
IPC分类号: A61K31/4965 , A61K31/439 , C07D241/04
CPC分类号: C07D295/26 , A61K31/445 , A61K31/4453 , A61K31/495 , A61K31/5375 , A61K31/54 , A61K45/06 , C07D211/96 , C07D241/04 , C07D241/08 , C07D265/30
摘要: Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists of Formula I or II, and pharmaceutical compositions thereof: wherein X, Y, Z, and R1-R5 are as defined herein. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
摘要翻译: 本文提供式I或II的2,5-二取代芳基磺酰胺CCR3拮抗剂及其药物组合物:其中X,Y,Z和R 1 -R 5如本文所定义。 本文还提供其用于治疗,预防或改善CCR3介导的病症,疾病或病症的一种或多种症状的方法。
-
公开(公告)号:US20110230487A1
公开(公告)日:2011-09-22
申请号:US13050831
申请日:2011-03-17
IPC分类号: A61K31/5377 , C07D211/96 , A61K31/4468 , C07D401/12 , A61K31/454 , C07D413/12 , C07D401/04 , A61K31/4545 , A61K31/496 , A61P11/00 , A61P37/08 , A61P1/00 , A61P17/00 , A61P25/28 , A61P9/00 , A61P19/02 , C12N5/07
CPC分类号: C07D211/96 , A61K31/4468 , A61K31/4525 , C07D401/04 , C07D405/12 , C07D413/12 , C07D417/12
摘要: Provided herein are arylsulfonamides that are useful for modulating CCR3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.
摘要翻译: 本文提供了可用于调节CCR3活性的芳基磺酰胺及其药物组合物。 本文还提供其用于治疗,预防或改善CCR3介导的病症,疾病或病症的一种或多种症状的方法。
-
-
-
-
-
-
-